Oslo, Norway, 30 April 2024 Vistin Pharma ASA (OSE: VISTN), please find attached the call for the Annual General Meeting in Vistin Pharma, to be held on 23 May 2024 at 13:00 CEST. A physical...
Oslo, Norway, 24th of April 2024 Vistin Pharma ASA (VISTN) today announces the financial results for the first quarter of 2024. Revenue in the first quarter ended at MNOK 104 compared to...
Oslo, Norway, 24 April 2024 Please find attached the Annual Report for 2023 for Vistin Pharma ASA. There are no material changes in the financial statements compared to the preliminary full...
Oslo, Norway, 16 April 2024 Vistin Pharma ASA will release its first quarter results on Wednesday 24th of April 2024. Vistin Pharma will host a conference call for all shareholders and interested...
Pactum Vekst AS has on March 22, 2024 sold 527 960 shares in Vistin Pharma ASA at a price of NOK 22,10 per share. Espen W. Marcussen, Chair of the board in Pactum Vekst AS, is a primary insider and...
Vistin Pharma ASA: Fourth quarter and preliminary 2023 financial results
Vistin Pharma ASA: Key information relating to the proposed cash dividend
Oslo, Norway, 9 February 2024 Vistin Pharma ASA will release its fourth quarter and preliminary 2023 results on Friday 16th of February 2024. Vistin Pharma will host a conference call for all...
The shares in Vistin Pharma ASA will be traded ex dividend NOK 0.75 as from today, 23.01.2024. ...
Oslo, Norway, 11 January 2024 Norwegian pharmaceutical company Vistin Pharma ASA (Vistin Pharma) announced today that the Board has decided for a dividend of NOK 0.75 per share. The dividend is...